Latest News

Important Public Health Update on GLP-1 RAs

​

Health Canada Marketed Health Products Directorate has issued the following information regarding a summary safety review for Glucagon-like Peptide 1 Receptor Agonists (GLP-1 RAs) (dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide)

 

​